Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2005

View Archived Issues

Draxis amalgamates two subsidiaries

Alliance and LEO Pharma to enter Oxygent agreement for Europe and Canada

Positive results from confirmatory phase III study of Lauriad

Topline results of phase III orBec study

Nippon Kayaku to develop IL13-PE38QQR in Japan

Phase III protocol submitted for Multikine

Enrollment completed in Rebif vs. Copaxone comparative study

Phase I/II trial for TG-100-115 in heart attack patients

Vitae Pharmaceuticals, new name for Concurrent

Stellar International changes name to Stellar Pharmaceuticals

Phase Ib trials commence for next-generation Panzem

Treatment begins in phase I study of IMC-1121B in patients with solid tumors

Positive preclinical findings for Zeatin and cytokinin compounds

Arylchloroethylurea derivative exhibits antitumor activity in colon cancer model

Abraxane approved for metastatic breast cancer

ISTA launches Vitrase

Antithrombotic effects of fluvastatin tested in vitro

Rotarix launched in Mexico

Acute and chronic treatment with JTE-607 is effective in a mouse septic shock model

Rotigotine patch effective in moderate to severe restless legs syndrome

Macrolide antiinflammatory agents patented by Pliva

CRF-1 receptor antagonists in early development at Pfizer

Merck patent discloses synthesis of novel chemokine CCR2 receptor modulators

Phospholipase inhibitors prepared and tested at Lilly

Elan/Pfizer collaboration produces novel BACE inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...